DocWire News Editors

DocwireNews

Personalized risk assessments and new cholesterol-lowering therapies were among the new key recommendation of the American Heart Association/American College of Cardiology 2018 Cholesterol Guidelines, presented at the American Heart Association 2018 Scientific Sessions in Chicago.&ldquo;The updated guidelines reinforce the importance of healthy living, lifestyle modification and prevention. They build on the major shift we made in our 2013 cholesterol recommendations to focus on identifying and addressing lifetime risks for cardiovascular disease (CVD),&rdquo; said Ivor Benjamin, MD, FAHA, president of the American Heart Association, in a press release. &ldquo;Having high cholesterol at any age increases that risk significantly. That&rsquo;s why it&rsquo;s so important that even at a young age, people follow a heart-heathy lifestyle and understand and maintain healthy cholesterol levels.&rdquo;The guidelines contained several updates and tools practitioners can use. The CVD risk calculator, introduced in the 2013 guidelines, is an essential tool in the armamentarium for identifying a patient&rsquo;s 10-year risk for CVD. The 2018 guidelines encourage practitioners, in addition to following the results of the risk calculator, to talk with their patients about &ldquo;risk-enhancing factors,&rdquo; with the goal of providing a more personalized risk perspective. Some of these risk-enhancing factors include family history, ethnicity, conditions like metabolic syndrome, chronic kidney disease, inflammatory conditions, menopause, preeclampsia and high lipid markers.For high-risk patients with previous MI or stroke and whose elevated LDL-C levels are not well controlled by statin therapy, the 2018 guidelines make a recommendation for a step-wise for ezetimibe, added to a statin regimen, and then a PCSK9 inhibitor if ezetimibe is not working. One potential hurdle noted was the cost of PCSK9 inhibitors, which insurers have been slow to cover.&nbsp; In an encouraging sign, Dr. Benjamin reported that this may be beginning to change.&ldquo;The Association is bringing together stakeholders to discuss financial barriers to the care of heart disease and stroke,&rdquo; he said in a press release. &ldquo;We have been heartened that drug makers have recently agreed to reduce the prices of PSCK9 inhibitors and are making arrangements with payors to ease the financial burden for patients who could benefit from the additional medication options.&rdquo;Other important take-home messages from the 2018 guidelines included continual emphasis on a heart-healthy lifestyle across life course and an increased emphasis on the use of coronary artery calcium scores in certain patients who areThe guidelines were published along with a special companion <a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000638">report</a> summarizing the rationale and evidence for quantitative risk assessment. The report also reviewed the limitations and strengths of risk scores, discussed individualized risk assessment approaches, and provided advice for risk assessment and decision-making strategies in clinical practice.Read the full AHA/ACC 2018 Cholesterol Guidelines in <a href="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625">Circulation</a> or <a href="http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003">JACC</a>.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Individualized Risk Assessment, New LDL-lowering Options Among Highlights in 2018 AHA/ACC Cholesterol Guidelines

AHA Scientific Sessions 2018

Personalized risk assessments and new cholesterol-lowering therapies were among the new key recommendation of the American Heart Association/American College of Cardiology ...

Individualized Risk Assessment, New LDL-lowering Options Among Highlights in 2018 AHA/ACC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe